(Total Views: 112)
Posted On: 09/11/2024 1:41:19 PM
Post# of 36224
$CBDW News!1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company
1606 Corp. (OTC Pink:CBDW), a leader in AI technology development, is pleased to announce that it has signed a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus, a pioneering company at the forefront of Artificial Intelligence innovations in early drug discovery and infectious disease research.
This potential strategic investment underscores 1606 Corp.'s commitment to expanding its technological footprint and enhancing its capabilities in the rapidly evolving field of AI. We believe the integration of Adnexus's cutting-edge AI research and development expertise would significantly bolster 1606 Corp.'s portfolio, bringing advanced solutions to the intersection of artificial intelligence and healthcare and biotech.
Adnexus has been recognized for its groundbreaking work in leveraging AI to drive early drug discovery and develop critical treatments for infectious diseases including HIV and SARS-COV-2. By aligning with Adnexus, 1606 Corp. aims to accelerate innovation and development within the healthcare sector, combining its strengths in conversational AI and chatbot technology with Adnexus's pioneering research efforts. For a deeper dive into Adnexus' groundbreaking technology, visit their website at www.adnexusbiotech.com.
https://finance.yahoo.com/news/1606-corp-sign...00809.html
1606 Corp. (OTC Pink:CBDW), a leader in AI technology development, is pleased to announce that it has signed a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus, a pioneering company at the forefront of Artificial Intelligence innovations in early drug discovery and infectious disease research.
This potential strategic investment underscores 1606 Corp.'s commitment to expanding its technological footprint and enhancing its capabilities in the rapidly evolving field of AI. We believe the integration of Adnexus's cutting-edge AI research and development expertise would significantly bolster 1606 Corp.'s portfolio, bringing advanced solutions to the intersection of artificial intelligence and healthcare and biotech.
Adnexus has been recognized for its groundbreaking work in leveraging AI to drive early drug discovery and develop critical treatments for infectious diseases including HIV and SARS-COV-2. By aligning with Adnexus, 1606 Corp. aims to accelerate innovation and development within the healthcare sector, combining its strengths in conversational AI and chatbot technology with Adnexus's pioneering research efforts. For a deeper dive into Adnexus' groundbreaking technology, visit their website at www.adnexusbiotech.com.
https://finance.yahoo.com/news/1606-corp-sign...00809.html
(0)
(0)
